Home Latest Articles
Latest Articles
  • Manqi LI, Liping WEI, Qiaoyu TAO, Weiwei HE, Yan CHANG
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1671-1682.

    The efficient delivery of genes to target tissues or target cells by vectors is a critical step in gene therapy. Selecting a suitable, safe, and effective gene delivery vector is an urgent task in gene therapy. Gene therapy delivery vectors can be divided into two categories, viral vectors and nonviral vectors. In this review, the current application status and safety of viral vectors, synthetic nonviral vectors, and biological nonviral vectors are summarized, and the advantages and disadvantages of various delivery vectors are compared. Furthermore, the key points for evaluating the nonclinical safety of gene delivery vectors are summarized to provide references for the selection, application, and safety evaluation of vectors in the field of gene therapy.

  • Wangding LU, Yuanyuan GE, Guiliang CHEN, Jian WANG, Jun HE, Huafei LUO, Jingchen ZHANG
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1683-1688.

    Drug-device combination products are a special class of drug product with relatively high technical barriers. The research of their generic products has been a hot and difficult issue. However, the success rate of the product development is extremely low. Compared with ordinary dosage forms, human factor should be systematically considered in the development of generic drug-device products. Currently, there is no guideline for human factors engineering research in China. This study conducts a comparative analysis of factors based on the latest guidelines from FDA, such as"Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry ", and "Bridging for Drug-Device and Biologic-Device Combination Products: Draft Guidance for Industry ". Several case studies are applied for the illustration of some key considerations on development of generic drug-device combination products to provide a reference for researchers.

  • Jiayi YU, Yimeng HAO, Jing MA
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1689-1698.

    Protein drugs include therapeutic proteins with enzymatic or regulatory activity, targeted protein such as antibody drugs, protein vaccines and protein diagnostics. Protein drugs have been one of the most focused areas in new drug development due to their strong specificity, slight adverse drug reaction and significant therapeutic effect. With the rapid development of protein drugs, higher requirements are put forward for their bioanalysis methods. To support the research of pharmacokinetics and toxicokinetics, more sensitive, accurate and high-throughput bioanalytical methods need to be established. In recent years, LC-MS/MS has emerged as a promising and versatile tool for quantitative analysis of protein drugs, owing to its rapid development. In this study, the application progress of LC-MS/MS to the quantitative analysis of protein drugs is summarized, and the specific experimental process of bottom-up analysis method in detail is introduced, which provides a reference for the study of LC-MS/MS in the determination of protein drugs.

  • Xinyang LIU, Shuiping OU, Yun ZHAO, Ming YANG, Sen WANG
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1699-1705.

    The selection of an effective taste masking technique is the key to improving the taste of drugs, and the research on drug taste masking techniques focuses on the sensitivity and accuracy of bitterness evaluation methods. This paper aims to review the in vivo and in vitro evaluation techniques of drug bitterness, and put an emphasis on advantages, disadvantages, and applicability of these techniques. It is suggested that the scope of determination should be standardized after the evaluation by traditional human taste panel method under the premise of ensuring safety, and then other methods, for example, electronic tongue method, should be used to screen other similar preparations and formulations to provide some references for bitter taste masking research.

  • Ying ZHAO, Kexin XU, Hao HU, Huimei WANG, Lianyan WANG
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1706-1714.

    In the treatment of bladder dysfunctional diseases and bladder tumors, as an emerging therapeutic strategy, nanotechnology provides promising applications for efficient drug delivery in vivo due to its effective size effect and targeting modifications. As an effective administration route for the treatment of bladder diseases, intravesical instillation shows superior efficacy compared with systemic administration. However, periodic urination flushes out the instilled drug, resulting in a reduced duration of action. In addition, the existence of a bladder permeability barrier limits drug penetration into the inflammatory sites and tumor tissues. Therefore, it is crucial to develop a novel nano-drug delivery system. This study reviews researches related to nano-drug delivery systems for the treatment of bladder dysfunctional diseases and bladder tumors, with the aim of providing more ideas and methods for improvement of clinical treatments in the future.

  • Longlong JIN, Yajun ZHANG, Huimin SUN, Yong LU, Xianfu WU
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1715-1718.

    In order to perform the quality control of mifepristone(1), its 17-stereoisomer, 11β-[4-(N, N-dimethylamino)-1-phenyl]-17α-hydroxy-17β-(1-propinyl)-estra-4,9-dien-3-one(1'), was synthesized. The target product 1' was prepared from easily available 1 via esterification with fuming nitric acid, hydrolysis and inversion of configuration in the presence of AgNO3, with a purity of more than 95%. Meanwhile, its absolute configuration (8S,11R,13S,14S,17R) was determined by electronic circular dichroism.

  • Jingyi ZHANG, Jianwei ZHU, Baohong ZHANG
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1719-1725.

    The split intein, Nostoc punctiforme(Npu) DnaE, is a site-specific conjugating tool for antibody-drug conjugates(ADC). Its splicing activity is affected by the lysine residues in the C-terminal sequence. This study focused on the splicing activities of different lysine mutants in the C-terminal sequence of Npu DnaE. Five amino acid(arginine, glutamine, glycine, glutamic acid and methionine) mutants were performed to explore the effects of different site-directed mutagenesis on lysine in the C-terminal sequence of the split intein Npu DnaE. The results showed that substitutions of lysine in the C-terminus by arginine, glutamine and methionine maintained splicing activity, and the arginine-substituted C-terminus exhibited the higher splicing efficiency. The ADC, HER2-Lc-SMCC-DM1, was further produced by split intein with arginine-substituted C-terminus, and both the antigen affinity and bioactivity were retained. This research provided technical support for site-specific ADC and protein/peptide synthesis based on the application of the intein.

  • Xiaoming ZHANG, Ying HUANG, Yuling LIANG, Jing LI, Chenggang LIANG
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1726-1734.

    A cell-based method for recombinant human growth hormone(rhGH) bioactivity evaluation was established to replace in vivo animal experiments. Different concentrations of rhGH were used to stimulate the proliferation of the Nb-2 rat lymphoma cell line(Nb2-11 cell) and luminescent cell viability assay was used to measure the cell proliferation to evaluate the bioactivity of rhGH. The relative potency of rhGH was calculated by the 4-parameter logistic(4PL) regression model. Then, the method parameters were optimized. The specificity, relative accuracy, precision, and linearity of this method were verified. The results showed that this method had good specificity, and the relative bias for relative accuracy range was –6.2% - 0.9%, the correlation coefficient of the linear regression equation was 0.985 0, the geometric coefficient of variation for intermediate precision range was 5.2% - 7.7%, the linear range was 50% - 200%. The biological activities of 15 batches of rhGH products were investigated by the Nb2-11 cell proliferation method and the in vivo animal experiment, respectively. The results showed that these two methods had a good consistency. In this study, the Nb2-11 cell proliferation method for determination of rhGH bioactivity was established and verified, and it could be used as a routine method for rhGH bioactivity evaluation and quality control.

  • Lijia YUAN, Guanru WANG, Junfeng LIU, Jun HE
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1735-1742.

    Docetaxel(1) is a milestone drug in the field of tumor therapy. However, the marketed 1 injection uses Tween-80 and ethyl alcohol as solubilizers, which is prone to induce allergy and hemolysis, and patients have to take glucocorticoids and antihistaminics prior to administration. According to the feature of 1, two 1-loading formulations were prepared, namely sulfobutylether-β-cyclodextrin(SBE-β-CD) inclusion complexes and long-circulating nanoemulsions. Taking SBE-β-CD as the main body of the complexes, the molar ratio of 1 to SBE-β-CD was set at 1∶70 to prepare SBE-β-CD inclusion complexes of 1, and the formation of these inclusion complexes was verified by X-ray diffraction and differential scanning calorimetry(DSC). The composite emulsifier of 1-loading long-circulating nanoemulsions was screened out by pseudo-ternary phase diagram, and average particle size of the obtained nanoemulsions was 53.3 nm with polydispersity index(PDI) of 0.115. The results of in vitro release test showed that (83.48±3.11)% of 1 released from the SBE-β-CD inclusion complexes within 48 hours in phosphate buffer containing 0.5% Tween-80, while (77.60±4.15)% of 1 released from the long-circulating nanoemulsions within 96 hours. The results of the cytotoxicity test showed that the IC50 values of 1 solution, the inclusion complexes and the long-circulating nanoemulsions against 4T1 murine breast cancer cells were 1.50, 0.45 and 0.30 μg/ml, respectively. The pharmacokinetics in rats showed that compared with the commercial injection, the clearance(Cl) values of the inclusion complexes and the long-circulating nanoemulsions were significantly decreased, while the AUC values were significantly increased, showing a good in vivo sustained-release effect.

  • Junfeng LIU, Junji WANG, Yuan ZHAO, Qin LI, Jun HE
    Chinese Journal of Pharmaceuticals. 2022, 53(12): 1743-1751.

    The nano- and micro-suspensions loaded with meloxicam(1) were prepared by wet milling process and microfluidic homogenization method, respectively. Their formulations and process parameters were optimized and characterized. And the in vitro and in vivo release behaviors of nano- and micro-suspensions were investigated. The in vitro release test was carried out with the dispersion releaser device. The results showed that the release plateau of the nanosuspensions was shortened by 12 h, compared with the microsuspensions. The in vivo test with female SD rats as the models was adopted to investigate the pharmacokinetic behaviors of two kinds of suspensions of 1 after intramuscular injection. The results showed that compared with micro-suspensions, the tmax of nanosuspensions was significantly shortened (1.00 h vs. 16.00 h) and the cmax was increased (5.10 μg/ml vs. 4.20 μg/ml). However, both nanosuspensions and microsuspensions can maintain sustained-release profiles for 144 h. 1-Nanosuspensions with faster systemic absorption could be applied to relieve acute pain, and 1-microsuspensions with stable plasma concentration could be used for treatment of long-term pain.

News